PRTA Company Profile and Key Details

Q: Who are the executives of PRTA?

Ms. Carol D. KarpChief Regulatory OfficerDr. Hideki Garren M.D., Ph.D.Chief Medical OfficerMs. Karin L. Walker CPA, CPAChief Accounting Officer & ControllerMs. Jennifer ZibudaDirector of Investor Relations & CommunicationMr. Brandon S. SmithChief Operating OfficerMr. Michael J. MalecekChief Legal Officer & Company Sec.Dr. Gene G. Kinney Ph.D.Pres, Chief Executive Officer & DirectorDr. Wagner M. ZagoChief Scientific OfficerMs. Yvonne M. TchrakianCompany Sec.Mr. Tran B. Nguyen M.B.A.Chief Financial Officer & Chief Strategy Officer

NASDAQ : PRTA

Prothena

$9.95

-0.03-0.30%

Open: 12:29 PM

60.49

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Prothena Corporation plc (PRTA) stock declined over -0.30%, trading at $9.95 on NASDAQ, down from the previous close of $9.98. The stock opened at $9.89, fluctuating between $9.80 and $9.98 in the recent session.

Stock Snapshot

9.98

Prev. Close

520.91M

Market Cap

9.8

Day Low

-3.54

P/E Ratio

-2.81

EPS (TTM)

-2.55

Cash Flow per Share

9.89

Open

52.35M

Number of Shares

9.98

Day High

74.48%

Free Float in %

10.46

Book Value

154.95K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 28, 2026	9.95	10.05	9.93	9.98	281.81K
May 27, 2026	10.11	10.26	10.01	10.03	616.02K
May 26, 2026	9.84	10.07	9.45	10.06	918.63K
May 22, 2026	9.36	10.00	9.36	9.83	510.85K
May 21, 2026	9.16	9.42	9.04	9.41	388.72K
May 20, 2026	9.09	9.41	9.09	9.35	624.58K
May 19, 2026	9.61	9.84	9.02	9.07	627.3K
May 18, 2026	9.66	10.09	9.53	9.59	650.97K
May 15, 2026	9.73	9.86	9.46	9.76	699.76K
May 14, 2026	9.60	9.88	9.42	9.86	452.44K
May 13, 2026	9.33	9.73	9.28	9.60	530.78K
May 12, 2026	9.67	9.82	9.29	9.43	495.1K
May 11, 2026	10.79	10.88	9.46	9.67	843.78K
May 08, 2026	11.00	11.80	10.62	10.73	798.67K
May 07, 2026	11.10	11.21	10.40	10.52	442.89K
May 06, 2026	11.19	11.30	11.02	11.18	333.86K
May 05, 2026	10.89	11.25	10.89	11.19	305.9K
May 04, 2026	10.58	11.00	10.55	10.79	585.18K
Apr 30, 2026	10.89	11.12	10.84	11.06	295.66K
Apr 29, 2026	11.46	11.46	10.74	10.87	397.55K

Contact Details

Dublin, 2

Ireland

https://www.prothena.com 353 123 62500

About Company

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual A�-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Stock Peers

ARGX

17.86+2.18%

argenx SE$838.49 REGN

-6.22-0.99%

Regeneron Pharmaceuticals, Inc.$621.52 UTHR

-8.66-1.52%

United Therapeutics Corporation$562.09 MDGL

-11.71-2.22%

Madrigal Pharmaceuticals, Inc.$515.96 VRTX

10.75001+2.46%

Vertex Pharmaceuticals Incorporated$447.97 PRAX

-4.5-1.26%

Praxis Precision Medicines, Inc.$352.63 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

3.67+1.20%

Krystal Biotech, Inc.$310.30 ALNY

9.43+3.19%

Alnylam Pharmaceuticals, Inc.$305.06 ASND

2.21+0.94%

Ascendis Pharma A/S$237.47

Frequently Asked Questions

What is the current Prothena Corporation plc (PRTA) stock price?

Prothena Corporation plc (NASDAQ: PRTA) stock price is $9.95 in the last trading session. During the trading session, PRTA stock reached the peak price of $9.98 while $9.80 was the lowest point it dropped to. The percentage change in PRTA stock occurred in the recent session was -0.3% while the dollar amount for the price change in PRTA stock was - $0.03.

PRTA's industry and sector of operation?

The NASDAQ listed PRTA is part of Biotechnology industry that operates in the broader Healthcare sector. Prothena Corporation plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRTA?

Ms. Carol D. Karp
Chief Regulatory Officer
Dr. Hideki Garren M.D., Ph.D.
Chief Medical Officer
Ms. Karin L. Walker CPA, CPA
Chief Accounting Officer & Controller
Ms. Jennifer Zibuda
Director of Investor Relations & Communication
Mr. Brandon S. Smith
Chief Operating Officer
Mr. Michael J. Malecek
Chief Legal Officer & Company Sec.
Dr. Gene G. Kinney Ph.D.
Pres, Chief Executive Officer & Director
Dr. Wagner M. Zago
Chief Scientific Officer
Ms. Yvonne M. Tchrakian
Company Sec.
Mr. Tran B. Nguyen M.B.A.
Chief Financial Officer & Chief Strategy Officer

How PRTA did perform over past 52-week?

PRTA's closing price is 125.69% higher than its 52-week low of $4.42 where as its distance from 52-week high of $11.80 is -15.42%.

How many employees does PRTA have?

Number of PRTA employees currently stands at 163.

Link for PRTA official website?

Official Website of PRTA is: https://www.prothena.com

How do I contact PRTA?

PRTA could be contacted at phone 353 123 62500 and can also be accessed through its website. PRTA operates from 77 Sir John Rogerson’s Quay, Dublin, 2, Ireland.

How many shares of PRTA are traded daily?

PRTA stock volume for the day was 154.95K shares. The average number of PRTA shares traded daily for last 3 months was 577.19K.

What is the market cap of PRTA currently?

The market value of PRTA currently stands at $520.91M with its latest stock price at $9.95 and 52.35M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	163
Beta	-0.28
Sales or Revenue	$91.37M
5Y Sales Change%	70.122%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	163
Beta	-0.28
Sales or Revenue	$91.37M
5Y Sales Change%	70.122%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRTA Company Profile and Key Details

Prothena

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook